Screener
Nektar Therapeutics NKTR Total Cost of Revenue
Discontinued — last reported Q4 '25
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Nektar Therapeutics’s 10-K, filed March 13, 2026.
- Filed
- Mar 13, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-104547
| Line item | Year Ended December 31, | Year Ended December 31, | Year Ended December 31, |
|---|---|---|---|
| License, collaboration and other revenue | 300 | 597 | |
| Total revenue | 55,232 | 98,427 | |
| Operating costs and expenses: | |||
| Cost of goods sold | — | 30,686 | |
| Research and development (including $2,636 and $277 for the year ended December 31, 2025 and 2024, respectively, from a related party) | 117,330 | 120,908 | |
| General and administrative | 68,673 | 76,751 | |
| Restructuring and impairment | 9,331 | 15,670 | |
| Gain on sale of the Huntsville manufacturing facility | — | (40,390) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Nektar Therapeutics's total cost of revenue?
- Nektar Therapeutics (NKTR) reported total cost of revenue of $0 in Q4 2025.
- How has Nektar Therapeutics's total cost of revenue changed year-over-year?
- Nektar Therapeutics's total cost of revenue decreased by 100.0% year-over-year, from $7.98M to $0.
- What is the long-term trend for Nektar Therapeutics's total cost of revenue?
- Over 4 years (2021 to 2025), Nektar Therapeutics's total cost of revenue has grown at a -100.0% compound annual growth rate (CAGR), from $24.9M to $0.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Nektar Therapeutics's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude